| 000 | 01763 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250513230428.0 | ||
| 264 | 0 | _c20010419 | |
| 008 | 200104s 0 0 eng d | ||
| 022 | _a0007-1188 | ||
| 024 | 7 |
_a10.1038/sj.bjp.0703869 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPubill, D | |
| 245 | 0 | 0 |
_aOrphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. _h[electronic resource] |
| 260 |
_bBritish journal of pharmacology _cFeb 2001 |
||
| 300 |
_a693-702 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xtoxicity |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 |
_aBody Weight _xdrug effects |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aCerebellum _xcytology |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aIsoquinolines _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMortality |
| 650 | 0 | 4 |
_aMuscarinic Antagonists _xpharmacology |
| 650 | 0 | 4 |
_aNeurotoxicity Syndromes _xprevention & control |
| 650 | 0 | 4 | _aNitro Compounds |
| 650 | 0 | 4 |
_aOrphenadrine _xpharmacology |
| 650 | 0 | 4 |
_aPropionates _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRadioligand Assay |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aTritium |
| 700 | 1 | _aVerdaguer, E | |
| 700 | 1 | _aCanudas, A M | |
| 700 | 1 | _aSureda, F X | |
| 700 | 1 | _aEscubedo, E | |
| 700 | 1 | _aCamarasa, J | |
| 700 | 1 | _aPallàs, M | |
| 700 | 1 | _aCamins, A | |
| 773 | 0 |
_tBritish journal of pharmacology _gvol. 132 _gno. 3 _gp. 693-702 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bjp.0703869 _zAvailable from publisher's website |
| 999 |
_c11099229 _d11099229 |
||